Immunopathogenesis of inflammatory bowel diseases: Functional role of T cells and T cell homing

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 19-28

  Zundler, Sebastian ^a   Neurath, Markus F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cytokines; Gut homing; Inflammatory bowel diseases; Regulatory T lymphocytes

Indexed keywords

CHEMOKINE RECEPTOR CCR9; ETROLIZUMAB; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; STAT3 PROTEIN; ANTIINFLAMMATORY AGENT; AUTACOID; GASTROINTESTINAL AGENT;

ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTE HOMING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; TH9 CELL; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHENOTYPE; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOTAXIS, LEUKOCYTE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINES; PHENOTYPE; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84953345096     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (154)

1. DANESE S, FIOCCHI C: Ulcerative Colitis. N Engl J Med 2011; 365: 1713-25.
2. BAUMGART DC, SANDBORN WJ: Crohn's disease. The Lancet 2012; 380: 1590-605.
3. HUGOT JP, CHAMAILLARD M, ZOUALI H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
4. OGURA Y, BONEN DK, INOHARA N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
5. JOSTINS L, RIPKE S, WEERSMA RK et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
6. ANANTHAKRISHNAN AN: Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015; 12: 205-17.
7. KOSTIC AD, XAVIER RJ, GEVERS D: The microbiome in inflammatory bowel diseases: current status and the future ahead. Gastroenterology 2014; 146: 1489-99.
8. KLAG T, STANGE EF, WEHKAMP J: Defective antibacterial barrier in inflammatory bowel disease. Dig Dis Basel Switz 2013; 31: 310-6.
9. NEURATH MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329-42.
10. FUSS IJ, NEURATH M, BOIRIVANT M et al.: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-70.
11. ATREYA R, ZIMMER M, BARTSCH B et al.: Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology 2011; 141: 2026-38.
12. KAMADA N, HISAMATSU T, OKAMOTO S et al.: Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008; 118: 2269-80.
13. STROBER W, FUSS IJ, BLUMBERG RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549.
14. ZENEWICZ LA, ANTOV A, FLAVELL RA: CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15: 199-207.
15. KOBAYASHI T, OKAMOTO S, HISAMATSU T et al.: IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008; 57: 1682-9.
16. NEURATH MF, WEIGMANN B, FINOTTO S et al.: The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195: 1129-43.
17. ROVEDATTI L, KUDO T, BIANCHERI P et al.: Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009; 58: 1629-36.
18. BREESE E, BRAEGGER CP, CORRIGAN CJ, WALKER-SMITH JA, MacDONALD TT: Interleukin-2-and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78: 127-31.
19. FAIS S, CAPOBIANCHI MR, PALLONE F et al.: Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut 1991; 32: 403-7.
20. PARRELLO T, MONTELEONE G, CUCCHIARA S et al.: Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol 2000; 165: 7234-9.
21. ROMAGNANI S: Th1/Th2 Cells. [Review]. Inflamm Bowel Dis 1999; 5: 285-94.
22. SAKURABA A, SATO T, KAMADA N et al.: Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 2009; 137: 1736-45.
23. WIRTZ S, FINOTTO S, KANZLER S et al.: Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF-plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. J Immunol 1999; 162: 1884-8.
24. SIMPSON SJ, SHAH S, COMISKEY M et al.: T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 1998; 187: 1225-34.
25. NEURATH MF, FUSS I, KELSALL BL, STüBER E, STROBER W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-90.
26. POWRIE F, LEACH MW, MAUZE S et al.: Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1: 553-62.
27. REINISCH W, HOMMES DW, VAN ASSCHE G et al.: A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease. Gut 2006; 55: 1138-44.
28. YAGI R, ZHU J, PAUL WE: An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int Immunol 2011; 23: 415-20.
29. FUSS IJ, STROBER W: The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol 2008; 1 (Suppl. 1): S31-33.
30. HELLER F, FLORIAN P, BOJARSKI C et al.: Interleukin-13 Is the Key Effector Th2 Cytokine in Ulcerative Colitis That Affects Epithelial Tight Junctions, Apoptosis, and Cell Restitution. Gastroenterology 2005; 129: 550-64.
31. FUSS IJ: Is the Th1/Th2 paradigm of immune regulation applicable to IBD? Inflamm Bowel Dis 2008;.
32. ROSEN MJ, CHATURVEDI R, WASHINGTON MK et al.: STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. J Immunol 2013; 190: 1849-58.
33. HELLER F, FUSS IJ, NIEUWENHUIS EE, BLUMBERG RS, STROBER W: Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17: 629-38.
34. CAMELO A, BARLOW JL, DRYNAN LF et al.: Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol 2012; 47: 1198-211.
35. BIANCHERI P, DI SABATINO A, AMMOSCATO F et al.: Absence of a role for interleukin-13 in inflammatory bowel disease. Eur J Immunol 2014; 44: 370-85.
36. DANESE S, RUDZINSKI J, BRANDT W et al.: Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015; 64: 243-9.
37. REINISCH W, PANéS J, KHURANA S et al.: Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 2015; 64: 894-900.
38. SCHMITZ J, OWYANG A, OLDHAM E et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-90.
39. SEIDELIN JB, COSKUN M, KVIST PH et al.: IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J Gastroenterol 2015; 50: 180-90.
40. SEIDELIN JB, BJERRUM JT, COSKUN M et al.: IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 2010; 128: 80-5.
41. KOBORI A, YAGI Y, IMAEDA H et al.: Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010; 45: 999-1007.
42. BELTRAN CJ, NUNEZ LE, DIAZ-JIMENEZ D et al.: Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1097-107.
43. PASTORELLI L, GARG RR, HOANG SB et al.: Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010; 107: 8017-22.
44. SEDHOM MAK, PICHERY M, MURDOCH JR et al.: Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 2013; 62: 1714-23.
45. PUSHPARAJ PN, LI D, KOMAI-KOMA M et al.: Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 2013; 140: 70-7.
46. DUAN L, CHEN J, ZHANG H et al.: Interleukin-33 Ameliorates Experimental Colitis through Promoting Th2/Foxp3+ Regulatory T-Cell Responses in Mice. Mol Med 2012; 18: 753-61.
47. OPPMANN B, LESLEY R, BLOM B et al.: Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12. Immunity 2000; 13: 715-25.
48. CUA DJ, SHERLOCK J, CHEN Y et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-8.
49. LANGRISH CL, CHEN Y, BLUMENSCHEIN WM et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-40.
50. VOLPE E, SERVANT N, ZOLLINGER R et al.: A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008; 9: 650-7.
51. SUTTON C, BRERETON C, KEOGH B, MILLS KHG, LAVELLE EC: A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203: 1685-91.
52. FINA D, SARRA M, FANTINI MC et al.: Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134: 103848.
53. KAMADA N, HISAMATSU T, HONDA H et al.: TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 2010; 16: 568-75.
54. HIRAHARA K, GHORESCHI K, LAURENCE A et al.: Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 2010; 21: 425-34.
55. MONTELEONE I, PALLONE F, MONTELEONE G: Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med 2011; 9: 122.
56. DAMBACHER J, BEIGEL F, ZITZMANN K et al.: The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009; 58: 1207-17.
57. BECKER C, WIRTZ S, BLESSING M et al.: Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003; 112: 693-706.
58. IVANOV II, ATARASHI K, MANEL N et al.: Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-98.
59. JIANG W, SU J, ZHANG X et al.: Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 2014; 63: 943-50.
60. OLSEN T, RISMO R, CUI G et al.: TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011; 56: 633-40.
61. KLEINSCHEK MA, BONIFACE K, SADEKOVA S et al.: Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009; 206: 525-34.
62. MUDTER J, YU J, ZUFFEREY C et al.: IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo. Inflamm Bowel Dis 2011; 17: 1343-58.
63. MUDTER J, AMOUSSINA L, SCHENK M et al.: The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest 2008; 118: 2415-26.
64. LEPPKES M, BECKER C, IVANOV II et al.: RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009; 136: 257-67.
65. AHERN PP, SCHIERING C, BUONOCORE S et al.: Interleukin-23 drives intestinal inflammation through direct activity on t cells. Immunity 2010; 33: 279-88.
66. O'CONNOR W, KAMANAKA M, BOOTH CJ et al.: A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009; 10: 603-9.
67. OGAWA A, ANDOH A, ARAKI Y, BAMBA T, FUJIYAMA Y: Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004; 110: 55-62.
68. FOSSIEZ F, DJOSSOU O, CHOMARAT P et al.: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-603.
69. JOVANOVIC DV, BATTISTA JAD, MARTEL-PELLETIER J et al.: IL-17 Stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J Immunol 1998; 160: 3513-21.
70. PARK H, LI Z, YANG XO et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-41.
71. HUEBER W, SANDS BE, LEWITZKY S et al.: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693-700.
72. HIROTA K, DUARTE JH, VELDHOEN M et al.: Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011; 12: 255-63.
73. LEE YK, TURNER H, MAYNARD CL et al.: Late developmental plasticity in the T helper 17 lineage. Immunity 2009; 30: 92-107.
74. ANNUNZIATO F, COSMI L, SANTARLASCI V et al.: Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204: 1849-61.
75. SUJINO T, KANAI T, ONO Y et al.: Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. Gastroenterology 2011; 141: 1014-23.
76. LIU H-P, CAO AT, FENG T et al.: TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression. Eur J Immunol 2015; 45: 1010-8.
77. VELDHOEN M, UYTTENHOVE C, van SNICK J et al.: Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9: 1341-6.
78. STAUDT V, BOTHUR E, KLEIN M et al.: Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells. Immunity 2010; 33: 192-202.
79. CHANG H-C, SEHRA S, GOSWAMI R et al.: The transcription factor PU.1 is required for the development of interleukin 9-producing T cells and allergic inflammation. Nat Immunol 2010; 11: 527-34.
80. TAN C, GERY I: The Unique Features of Th9 Cells and their Products. Crit Rev Immunol 2012; 32: 1-10.
81. ZHAO P, XIAO X, GHOBRIAL RM, LI XC: IL-9 and Th9 cells: progress and challenges. Int Immunol 2013; 25: 547-51.
82. CHANG H-C, HAN L, JABEEN R et al.: PU.1 regulates TCR expression by modulating GATA-3 activity. J Immunol 2009; 183: 4887-94.
83. DARDALHON V, AWASTHI A, KWON H et al.: Interleukin 4 inhibits TGF-β-induced-Foxp3+T cells and generates, in combination with TGF-β, Foxp3-effector T cells that produce interleukins 9 and 10. Nat Immunol 2008; 9: 1347-55.
84. XIAO X, BALASUBRAMANIAN S, LIU W et al.: OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol 2012; 13: 981-90.
85. LU Y, HONG S, LI H et al.: Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012; 122: 4160-71.
86. PURWAR R, SCHLAPBACH C, XIAO S et al.: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18: 1248-53.
87. JäGER A, DARDALHON V, SOBEL RA, BETTELLI E, KUCHROO VK: Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009; 183: 7169-77.
88. GERLACH K, HWANG Y, NIKOLAEV A et al.: TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol 2014; 15: 676-86.
89. NALLEWEG N, CHIRIAC MT, PODSTAWA E et al.: IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut 2015; 64: 743-55.
90. GERLACH K, McKENZIE AN, NEURATH MF, WEIGMANN B: IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. Tissue Barriers 2015; 3: e983777.
91. TRIFARI S, KAPLAN CD, TRAN EH, CRELLIN NK, SPITS H: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009; 10: 864-71.
92. DUHEN T, GEIGER R, JARROSSAY D, LANZAVECCHIA A, SALLUSTO F: Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10: 857-63.
93. ZENEWICZ LA, YANCOPOULOS GD, VALENZUELA DM et al.: Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-57.
94. SUGIMOTO K, OGAWA A, MIZOGUCHI E et al.: IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534-44.
95. PICKERT G, NEUFERT C, LEPPKES M et al.: STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206: 1465-72.
96. BACKERT I, KORALOV SB, WIRTZ S et al.: STAT3 Activation in Th17 and Th22 Cells Controls IL-22-Mediated Epithelial Host Defense during Infectious Colitis. J Immunol 2014; 193: 3779-91.
97. MIZOGUCHI A: Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis 2012; 18: 1777-84.
98. MONTELEONE I, RIZZO A, SARRA M et al.: Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011; 141: 237-48, 248.e1.
99. KAMANAKA M, HUBER S, ZENEWICZ LA et al.: Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med 2011; 208: 1027-40.
100. HORI S, NOMURA T, SAKAGUCHI S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
101. FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-6.
102. ZHENG Y, JOSEFOWICZ S, CHAUDHRY A et al.: Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463: 808-12.
103. ALMEIDA ARM, LEGRAND N, PAPIERNIK M, FREITAS AA: Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002; 169: 4850-60.
104. CHEN W, JIN W, HARDEGEN N et al.: Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-86.
105. MONTELEONE G, KUMBEROVA A, CROFT NM et al.: Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-9.
106. YAMAGIWA S, GRAY JD, HASHIMOTO S, HORWITZ DA: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001; 166: 7282-9.
107. MUCIDA D, PARK Y, KIM G et al.: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317: 256-60.
108. BAI A, LU N, GUO Y et al.: All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J Leukoc Biol 2009; 86: 959-69.
109. SMITH PM, HOWITT MR, PANIKOV N et al.: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-73.
110. FURUSAWA Y, OBATA Y, FUKUDA S et al.: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-50.
111. CHEN W, FRANK ME, JIN W, WAHL SM: TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14: 715-25.
112. FANTINI MC, RIZZO A, FINA D et al.: Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 2009; 136: 1308-16, e1-3.
113. RUBTSOV YP, RASMUSSEN JP, CHI EY et al.: Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008; 28: 546-58.
114. COLLISON LW, WORKMAN CJ, KUO TT et al.: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-9.
115. READ S, GREENWALD R, IZCUE A et al.: Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177: 4376-83.
116. SANTUCCI L, AGOSTINI M, BRUSCOLI S et al.: GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice. Gut 2007; 56: 52-60.
117. GARíN MI, CHU C-C, GOLSHAYAN D et al.: Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109: 2058-65.
118. DAVIDSON NJ, LEACH MW, FORT MM et al.: T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996; 184: 241-51.
119. HAHM KB, IM YH, PARKS TW et al.: Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001; 49: 190-8.
120. POWRIE F, LEACH MW, MAUZE S, CADDLE LB, COFFMAN RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5: 1461-71.
121. FANTINI MC, BECKER C, TUBBE I et al.: Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006; 55: 671-80.
122. ASSEMAN C, MAUZE S, LEACH MW, COFFMAN RL, POWRIE F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995-1004.
123. NAKAMURA K, KITANI A, FUSS I et al.: TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004; 172: 834-42.
124. MAUL J, LODDENKEMPER C, MUNDT P et al.: Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868-78.
125. YU QT, SARUTA M, AVANESYAN A et al.: Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2007; 13: 191-9.
126. DESREUMAUX P, FOUSSAT A, ALLEZ M et al.: Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 2012; 143: 1207-17.e1-2.
127. MONTELEONE G, NEURATH MF, ARDIZZONE S et al.: Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015; 372: 1104-13.
128. LEY K, LAUDANNA C, CYBULSKY MI, NOURSHARGH S: Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-89.
129. NOURSHARGH S, HORDIJK PL, SIXT M: Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat Rev Mol Cell Biol 2010; 11: 366-78.
130. GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
131. VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-8.
132. FEAGAN BG, RUTGEERTS P, SANDS BE et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
133. SANDBORN WJ, FEAGAN BG, RUTGEERTS P et al.: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.
134. CYSTER JG: Chemokines and Cell Migration in Secondary Lymphoid Organs. Science 1999; 286: 2098-102.
135. BERG EL, MCEVOY LM, BERLIN C, BARGATZE RF, BUTCHER EC: L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature 1993; 366: 695-8.
136. JOHANSSON-LINDBOM B, SVENSSON M, PABST O et al.: Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005; 202: 1063-73.
137. IWATA M, HIRAKIYAMA A, ESHIMA Y et al.: Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527-38.
138. BRISKIN M, WINSOR-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110.
139. AGACE WW: T-cell recruitment to the intestinal mucosa. Trends Immunol 2008; 29: 514.22.
140. ARSENEAU K, COMINELLI F: Targeting Leukocyte Trafficking for the Treatment of Inflammatory Bowel Disease. Clin Pharmacol Ther 2015; 97: 22-8.
141. VERMEIRE S, SANDBORN W, DANESE S et al.: OP021. TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in patients with moderate to severe Ulcerative Colitis (UC). J Crohns Colitis 2015; 9: S13-S13.
142. VERMEIRE S, O'BYRNE S, KEIR M et al.: Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014; 384: 309-18.
143. ERICSSON A, SVENSSON M, ARYA A, AGACE WW: CCL25/CCR9 promotes the induction and function of CD103 on intestinal intraepithelial lymphocytes. Eur J Immunol 2004; 34: 2720-9.
144. CEPEK KL, PARKER CM, MADARA JL, BRENNER MB: Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 1993; 150: 3459-70.
145. SCHöN MP, ARYA A, MURPHY EA et al.: Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol 1999; 162: 6641-9.
146. OSHITANI N, WATANABE K, MAEDA K et al.: Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease. Int J Mol Med 2003; 12: 715-9.
147. STRAUCH UG, MUELLER RC, LI XY et al.: Integrin alpha E(CD103)beta 7 mediates adhesion to intestinal microvascular endothelial cell lines via an E-cadherin-independent interaction. J Immunol 2001; 166: 3506-14.
148. KIM SV, XIANG WV, KWAK C et al.: GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science 2013; 340: 1456-9.
149. NGUYEN LP, PAN J, DINH TT et al.: Role and species-specific expression of colon T cell homing receptor GPR15 in colitis. Nat Immunol 2015; 16: 207-13.
150. FISCHER A, ZUNDLER S, ATREYA R, et al: Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 2015 Jul 24 [Epub ahead of print].
151. ATREYA R, NEUMANN H, NEUFERT C et al.: In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014; 20: 313-8.
152. MORRISON SL: Two heads are better than one. Nat Biotechnol 2007; 25: 1233-4.
153. HANSON ML, HIXON JA, LI W et al.: Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 2014; 146: 210-21.e13.
154. VANDENBROUCKE K, de HAARD H, BEIRNAERT E et al.: Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2009; 3: 49-56.